ABSTRACT
INTRODUCTION
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are newly approved drugs that ameliorate hyperglycemia without increasing the risk of hypoglycemia or body weight gain compared with other glucose-lowering drugs [1] [2] [3] . Accordingly, they are included as one of the treatment options for combination therapy of type 2 diabetes mellitus (T2DM) in the current American Diabetes Association/ European Association for the Study of Diabetes treatment recommendations [4] . Because the amount of glucose filtered through the glomerulus and urinary glucose excretion (UGE) are correlated with renal function [5] , it is important to investigate the relationship between renal function/renal impairment and the efficacy of SGLT2
inhibitors. Indeed, it has been reported that the pharmacodynamics of SGLT2 inhibitors in diabetic subjects with renal impairment are consistent with the observation of reduced efficacy in these patients [6] , and that some SGLT2 inhibitors are contraindicated in patients with chronic kidney disease, or their daily dose might need to be reduced [6] .
Luseogliflozin is a highly selective and potent SGLT2 inhibitor [7, 8] approved for use as monotherapy or in combination with other antidiabetic drugs based on the results of the clinical trial program [9] [10] [11] .
In a pharmacokinetic/pharmacodynamic study involving Japanese patients with T2DM, a single dose of luseogliflozin significantly increased 24-h UGE and significantly decreased fasting blood glucose and 2-h postprandial plasma glucose in patients with normal renal function, mildly reduced renal function, or moderately reduced renal function, but not in patients with severely reduced renal function [12] . Similar findings have been reported for other SGLT2 inhibitors in pharmacokinetic/pharmacodynamic studies and longer term studies [6] . To our knowledge, however, no studies have investigated the relationship between reduced renal function and daily glucose variability in patients treated with a SGLT2 inhibitor.
Therefore, to investigate the potential impact of reduced renal function on 24-h glucose variability in patients treated with an SGLT2
inhibitor, we performed a subanalysis of our previously reported study in which patients were treated with luseogliflozin or placebo for 7 days in a crossover manner, with 24-h continuous glucose monitoring (CGM) starting on day 7 of treatment [13] .
METHODS

Ethics Statement
As previously described [13] , the study was obtained from all patients before enrolment. This study was registered with the Japan Pharmaceutical Information Center (identifier: JapicCTI-142548).
Study Design
In this double-blind, placebo-controlled, crossover study, 37 Japanese patients with T2DM inadequately controlled with diet and exercise (HbA1c 7.0-10.0%) whose estimated glomerular filtration rate (eGFR) was C45 mL/ 
Data Analysis
The primary endpoints of the original study were indices derived from CGM. Other efficacy endpoints were pharmacodynamic variables, including serum insulin concentrations, plasma glucagon concentrations, and urinary glucose concentrations (pooled urine and 24-h urine samples). The following variables were calculated using the CGM data: 24-h mean glucose, area under the curve (AUC), peak blood glucose concentration, time to peak blood glucose concentration, and blood glucose concentration in preprandial or fasting periods. The glucose concentration-time curves were analyzed for the following periods: 0-24 h, after breakfast (0-5 h), after lunch (5-11 h), after dinner (11-15 h) , and the sleeping period (15-24 h 
RESULTS
The demographic and baseline characteristics of the patients of each group are shown in Table 1 .
Although glucose-related variables tended to be lower in the mild-moderate group, there were no significant differences between groups.
The variations in 24-h glucose concentrations measured by CGM and the UGE rates on day 7 of treatment with luseogliflozin and placebo are shown in Fig. 1 .
The 24-h glucose variables derived from CGM are shown in Table 2 and the pharmacodynamic variables are shown in Table 3 .
Although glucose variability was consistently lower with luseogliflozin than with placebo in the normal and normal-mild groups, glucose variability was not consistently lower with luseogliflozin than with placebo in the mild-moderate group, because of the smaller change in postprandial glucose concentrations in this group.
The mean 24-h glucose was lower with luseogliflozin than with placebo in all three groups. However, the placebo-subtracted However, the placebo-subtracted changes in the cumulative UGE were smaller in the mild-moderate group than in the normal and normal-mild groups, and these differences were statistically significant between groups for all measurement times except after dinner (throughout the day: P = 0.007; after breakfast: P = 0.037; after lunch: P = 0.007; after dinner: P = 0.198; sleeping period: P = 0.050, ANOVA).
The serum insulin and plasma glucagon levels on day 7 in each treatment period are shown in Fig. 2 . The serum insulin concentrations were consistently lower throughout the day with luseogliflozin than with placebo. The AUCs for serum insulin after each meal, during the sleeping period, and from 0 to 24 h were also smaller with luseogliflozin than with placebo in all three groups. The plasma glucagon concentrations were higher throughout the 24-h measurement period with Data are mean ± standard deviation. The differences between groups were analyzed by one-way ANOVA Glucose: 1 mg/dL = 0.0556 mmol/L Insulin: 1 lU/mL = 6.945 pmol/L Glucagon: 1 pg/mL = 1 ng/L BMI body mass index, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, FPG fasting plasma glucose, HbA1c hemoglobin A1c, SBP systolic blood pressure a Between-group difference luseogliflozin than with placebo, and the AUCs for plasma glucagon were higher with luseogliflozin than with placebo in almost all period in all groups. The placebo-subtracted differences in serum insulin-and plasma glucose-related variables were not significantly different between groups.
DISCUSSION
In this post hoc subanalysis, we investigated the impact of renal function decline on the glucose-lowering effects of luseogliflozin, including 24-h glucose variability, as well as pharmacodynamic variables. For the purpose of this subanalysis, we divided the patients into three groups based on their baseline eGFR: normal renal function, normal-to-mildly reduced renal function, and mild-to-moderately reduced renal function.
There were no significant differences in the demographic and baseline characteristics of between groups of patients, with the exceptions of eGFR and urinary albumin corrected for urinary creatinine.
We noted some differences in the variables derived from 24-h CGM among the three groups of patients. Although luseogliflozin decreased the fasting glucose concentrations (i.e., before each meal and in the sleeping period) in all three groups, it did not significantly reduce the postprandial glucose concentrations relative to placebo in the mild-moderate group. Furthermore, consistent with our original findings [13] , luseogliflozin significantly increased the cumulative UGE 
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Values are derived from 24-h continuous glucose monitoring. Normally distributed variables are presented as the least-squares mean (95% confidence interval) and the differences between luseogliflozin and placebo were analyzed using a mixed-effects model, which included treatment, sequence and period as fixed effects and patients as a random effect. Non-normally distributed variables are presented as the median (interquartile range), and the differences between luseogliflozin and placebo were determined using Wilcoxon signed-rank test. Non-normally distributed variables Table 3 continued
Variables
Normal group (n 5 0.278 Table 3 continued
Normal group (n 5 Laboratory tests were performed using blood samples obtained over 24-h. Normally distributed variables are presented as the least-squares mean (95% confidence interval) and the differences between luseogliflozin and placebo were analyzed using a mixed-effects model, which included treatment, sequence and period as fixed effects and patients as a random effect. Non-normally distributed variables are presented as the median (interquartile range), and the differences between luseogliflozin and placebo were determined using Wilcoxon signed-rank test. To evaluate the difference between groups in the difference between luseogliflozin and Nevertheless, the placebo-subtracted change in fasting glucose was smaller in the mild-moderate group than in the other 
